## NOTICE - SOME ITEMS SUPERSEDED OR OBSOLETE

## Schedule Number: NC1-088-83-05

Some items in this schedule are either obsolete or have been superseded by new NARA approved records schedules. This information is accurate as of: <u>11/14/2022</u>

## **ACTIVE ITEMS**

These items, unless subsequently superseded, may be used by the agency to disposition records. It is the responsibility of the user to verify the items are still active.

All other items not listed below are active.

## SUPERSEDED AND OBSOLETE ITEMS

The remaining items on this schedule may no longer be used to disposition records. They are superseded, obsolete, filing instructions, non-records, or were lined off and not approved at the time of scheduling. References to more recent schedules are provided below as a courtesy. Some items listed here may have been previously annotated on the schedule itself.

Item 2 is superseded by N1-088-05-002, item 1.

Items 3 and 10 are superseded by N1-088-09-001, items 1.1.1, 1.1.2, and 1.1.3..

Item 9 superseded by N1-088-05-001, item 6.

Item 14 is superseded by N1-088-07-002, items 5.2 and 6.1.

Item 20 is superseded by N1-088-06-002, item 2.

Item 24 is superseded by N1-088-09-001, item 1.6.3.

Item 25 is superseded by N1-088-05-002, item 4.1.

Item 26 is superseded by N1-088-07-002, item 5.3.2.

As of 11/14/2022 NC1-088-83-05

REQUEST FOR RECORDS DISPOSITION AUTHORITY (See Instructions on reverse)		l	EAVE BLANK	
		JOB NO.		
		NC1-88-8	33 <b>-</b> 5	
TO: GENERAL SERVICES ADMINISTRATION, NATIONAL ARCHIVES AND RECORDS SERVICE, WASHI	NGTON, DC 20408	DATE RECEIVED		
1. FROM (AGENCY OR ESTABLISHMENT)		7		
Department of Health and Human Ser	vices	7-8-83	CATION TO AGEN	ICY
2. MAJOR SUBDIVISION Public Health Service		In accordance with the pro quest, including amendme	nts, is approved excep	it for items that may
3. MINOR SUBDIVISION Food and Drug Administration		be stamped "disposa! not approved" or "withdrawn" in co		rawn" in column 10.
4. NAME OF PERSON WITH WHOM TO CONFER Jaquelyn Tolson PHS Records Officer	5. TEL. EXT. 443-2055	7-17-84 Jah Mary Date Archivist of the United States		
6. CERTIFICATE OF AGENCY REPRESENTATIVE	<b>!</b>	<del></del>		·
I hereby certify that I am authorized to act for the that the records proposed for disposal in this this agency or will not be needed after the rete	Request of page	aining to the disposa e(s) are not now ne	l of the agence eded for the l	y's records; business of
☐ A Request for immediate dispos	sal.			
B Request for disposal after a retention.	specified period of	of time or requ	est for pe	rmanent
C. DATE D. SIGNATURE OF AGENCY REPRESENTATIVE	E E. TITLE	Manageme	ent	
6/28/83 / Luz C. Lux	DHHS Re	ecords/Officer		
	PTION OF ITEM es or Retention Periods)		9. SAMPLE OR JOB NO.	10. ACTION TAKEN

This request is for changes to the Food and Drug Administration Records Control Schedules approved by the Archivist on February 23, 1978 (NARS job No. NC 1-88-78-1) and on October 9, 1979 (NARS job No. 1-88-79-2). These changes are to reschedule the disposal of certain records presently disposable on an indefinite basis and to update the Schedule in general. The items listed include those files originated by the Offices of Drugs and New Drug Evaluation.  $| \quad (D-1)$ Drug Study Evaluation Reports Results of statistical analyses and other evaluations made in the course of studies of various drugs to determine their safety and efficacy. May include actual analyses material in addition to final reports. a. Original reports Transfer to a Federal Records Center 5 years after NC1-88-78+1/D-1 completion of study Destroy 20 years after completion of study. b. Report copies Destroy 1 year after completion of study. 37 items Joseph Reiff, FDA Records Officer

34053

MASS DATA CHANGE SHEET ATTACHED

STANDARD FORM 115 Revised April, 1975

Prescribed by General Services NOW MINIF MINICR CONT & SPONE GICHAN 101-11.4

Request for	r Records Disposition Authority—Continuation	NO	PAGE OF
7. ITEM NO.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	SAMPLE OR JOB NO	10. ACTION TAKEN
D-2	Deleted.		
2. (D-3)	DESI File		
·	DESI (Drug Efficacy Study Implementation) folders containing recommendations and proposals and related source material including initial and follow-up announcements, action step charts, accession number charts, technical publications on the drugs involved, and other references. Also, log books and bioavailability card files. This program is the revifor efficacy of drugs previously reviewed only for safety.	I	B-1/D-3
	a. DESI Folders		
	Destroy on completion of review of each product a verification of microform copy.	nd .	
	b. <u>Card files and Log Book</u>		
	Destroy at same time as related folder.		
•	c. <u>Microform Copies</u>		•
	Destroy 5 years after completion of entire DESI project and any resulting litigation.		
3. (D-4)	Clinical Investigator File		
	Documents used to evaluate the validity of research performed by clinical investigators.	NC1-88-78	3-1/D-4
	Transfer to FRC 1 year after completion of evaluation. Destroy 7 years after completion of evaluation unless needed for further reference.		
4. (D-5)	New Drug Applications (NDA's)		
918202	Applications from drug producers for approval to market new drugs (Form ED 356H). Includes clinical data, test results, other than promotional labeling, progress and other reports, adverse reactions, notices of terminations, withdrawals or approvals, EDA evaluations and recommendations, supporting material and related correspondence.		WITHDRAWN

Request	or Records Disposition Authority—Continuation		PAGE OF 3 11
7.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	9, SAMPLE OR JCB NO	10. ACTION TAKEN
	(Disposal instructions for these records will be submitted separately.)		
5. (D-6)	Investigative New Drugs (IND's)	4	
	Applications from drug producers to ship drugs in inter-state commerce for testing on human subjects (Form FD 1571). Includes amendments, formulations, progress and other reports, changes, FDA evaluations and recommendations and related correspondence.		WITHDRAWN
	(Disposal instructions for these records will be submitted separately.)		
6. (D-7)	Drug Master Files		E
·	Privileged information concerning drug producers such as personnel involved, facilities, drug formulations and production methods.		WITHDRAWN
•	(Disposal instructions for these records will be submitted separately.)		
D-8	Laboratory Services Monthly Reports	1	
	Work count data for Program Management System reports. Consists of documentation regarding animal housing, glassware, and media preparations.	NC1-88-78	-1/D-8
	Destroy I year after order has been filled.		
D-9	Media Requests		
	Orders from FDA professionals for culture media (Form FD 1979).	NC1-88-78	-1/D-9
	Destroy I year after order has been filled.		
D-10	Glasswares Orders		
	Orders from FDA professionals for laboratory glassware (Form FD 1903).	NC1-88-78	-1/D-10
	Destroy I year after order has been filled.		·
D-11	Deleted.		
115-203	Four copies, including original, to be submitted to the National Archives	STANDARI	FORM 115-A

Request f	or Records Disposition Authority—Continuation	J08 NO.		PAGE OF 1
7. ITEM NO	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)		9. SAMPLE OR JOS NO	10. ACTION TAKEN
7. (D-12)	<u>Standards</u>			
	Master and working standards for defining potency of batches of antibiotics submitted by producers. Chemical and microbiological test results conducted FDA resulting in standard approval. Related correspondence with producers. FDA certification of standards.	l by	NC1-88-78	−1/D−12
	Destroy when superseded or no longer needed for reference.			
D-13	Deleted.			
8.(D-14)	Certification Records			:
	Antibiotic certifications and related analytical da	ta.	NC1-88-78	-1/D-14
	a. Insulin certifications			·
	Destroy master lot certifications after 5 years			
	Destroy individual dosage certifications after years.	3		
	b. Other antibiotic certifications			
	Destroy source listings, both paper and microfo on 10/1/83 or 1 year after certification, which is later.	rms, ever	· ·	
	Destroy cross references at same time.			,
	c. Rejected requests for certification			
•	Destroy 5 years after date of rejection or last action, whichever is later.			
D-15	Regulatory Testing Records	-		
	Laboratory data sheets used for testing USP, NF, an IND samples. Sheets are used for completion of analysts' work sheets.	d	NC1-88-78	-1/D <b>-1</b> 5
	Destroy 5 years after preparation or when no longer needed for reference.			•

Request for	r Records Disposition Authority—Continuation		PAGE OF
7. ITEM NO	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	9. SAMPLE OR JOB NO	10. ACTION TAKEN
D-16	Proposals		
	Proposals to do research work related to drugs received from individuals, groups, and institutions. Used to review and determine missions, goals, and objectives.	NC1-88-78	-1/D <b>-1</b> 6
	Destroy 5 years after final action taken.		
7. (D-17)	Drug Recall Files		
·	Recommendations to take recall action, approvals, notification of action taken and extent; recall inspection reports; labels, samples, and photographs of recalled products; and related correspondences and documentation.	NC1-88-7	3-1/D-17
	a. Original documents		
	Transfer to FRC 5 years after recall action is effected.  Destroy 15 years after action is effected.	·	
	b. Copies		
	Destroy copies 1 year after action is effected.		
10. (D-18)	Drug Regulatory Activities		
	Collection records, labeling, analytical reports, certificates and affidavits, seizure reports, termination of action reports, notices and records of hearings, recomendations, criminal prosecution records, regulatory letters, injunctions and related documents pertaining to individual seizure actions.	NC1-88-7	8-1/D-18
	Transfer to FRC 5 years after a judgement has been entered or the seized products have been either destroyed, reconditioned, or released pursuant to a deposition of the case, whichever is later.		
	Destroy 20 years after judgement or desposition.		
	·		

Request for	Records Dispesition Authority—Continuation		PAGE OF
7. ITEM NO.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	9. SAMPLE OR JOB NO	10. ACTION TAKEN
D-19	Daily Regulatory and Compliance Reports  Format type reports listing each seizure, voluntary and involuntary recall, and other enforcement action taken against unsafe or ineffective drug products.	NC1-88-78	<b>-</b> 1/D <b>-</b> 19
	Destroy 5 years after preparation of report.		
11. (D-20)	Drug Product Problem Reports		
	Reports received by FDA in conjunction with USP/FDA Drug Product Defect Reporting System and Laboratory Product Problem Reporting system. This is a joint effort with the United States Pharmacopeia to ascertain what drugs and categories of drugs have above normal defects and laboratory testing difficulties.	NC1-88-	78-1/D-20
	Destroy 5 years after receipt of report.		·
D. (D-21)	Methadone Hospital Files		
į	Jackets from each hospital receiving shipments of methadone containing applications to administer it, related correspondence, and reports on use and results.	NC1-88-7	-1/D-21
,	Transfer to FRC 2 years after application is withdrawn or revoked. Destroy 7 years after application is withdrawn or revoked.		
13. (D-22)	Methadone Treatment Program	NC1-88-	8-1/D-22
	Jackets containing applications requesting approval to administer methadone in the treatment of drug addiction by clinics, doctors, etc. correspondence with them, establishment inspection reports, and other reports.		
	Transfer to FRC 2 years after application is withdrawn or revoked. Destroy ************************************		
	·		·

Request for	r Records Disposition Authority—Continuation	0	PAGE OF.
7. ITEM NO.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	9. SAMPLE OR JOB NO	10. ACTION TAKEN
14. (D-23)	Drug Registration File		
	Official establishment registration (Forms FD 1597 and 2656) from all drug producers and the distributors submitted annually in compliance with the Kefauver-Harris Amendment of 1962.	NC1-88-7	8-1/D-23
	Destroy 10 years after submission.		
15. (D-24)	Drug Listing Labeling File	,	·
	Labels and advertising material on certain drugs submitted in accordance with the Drug Listing Act of 1972 and the Survey of Marketed Drugs.	NC1-88-7	/B-1/D-24
	Destroy 10 years after submission.		
D-25	Deleted		
, (D-26)	Abbreviated New Drug Applications (ANDA's)	. •	
	Applications to produce drugs already approved for other manufacturers. File contents similar but less extensive than NDA's (see item D-5).		WITHDRAWN
	(Disposal instructions for these records will be submitted separately.)		
7. (D-27)	Form A File		
	Drug container labels and evidence submitted by manufacturers to substantiate the efficacy of drugs first approved during the period 1938-1962. Material is used to evaluate the efficacy of these products in light of improved analytical methods.	NC1-88-	78-1/D-27
	Destroy 5 years after completion of DESI project and any resulting litigation.		
18. (D-28)	Drug Experience Reports		
	Original and duplicate (pink) copies of FD 1639, Drug Experience Report, describing effects and circumstances of adverse reactions on users of drug products. Also, microform copies of these reports made by FDA. Reports		8–1/D–28
115203	Four copies, including original, to be submitted to the National Archives	CTANDAD	D FORM 115-A

Request f	or Records Disposition Authority - Continuation	• ,	PAGE OF 8 11
7.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retantion Periods)	SAMPLE OR JOB NO	10. ACTION TAKEN
	submitted by drug manufacturers and suppliers in conjunction with their NDA's (see item D-5) or independently by physicians, hospitals, etc., of the medical community. Used to evaluate the safety of drug products.		
	a. Original forms submitted by manufacturers & producers		WITHDRAWN
	File in appropriate NDA jacket after initial processing and retire as indicated in item D-5.		WILLDWAIN
	b. Original forms submitted by the medical community		
	Destroy after initial processing, including microfilming.		
	c. <u>Duplicate Copies</u>		
·	Destroy after initial processing.		
	d. Microform copies		
	Destroy 30 years after submission of report unless needed for further study.		
M.(D-29)	Advertisements and Promotional Labeling		•
	Copies of nonviolative advertisements and promotional labels for prescription drugs, including reminders, and which may be on film or tape. Also, Form FD 2253, Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use.	NC1-88-78	÷1/D−29
	Destroy 2 years after completion of review.		
20 (D-30)	ASTRO-4 Drug Information System (ADP)		٠
•	This system maintains a file of data on new drug applications (NDA's) and investigational new drugs (IND's) which includes such items as drug manufacturers, drug names, drug usage information, and status of drug applications. Used to generate reports which aid in the IND/NDA review process and for compliance purposes.	NC1-88-79	-2/D-30
115-203	Four copies, including original, to be submitted to the National Archives	STANDARD	FORM 115-A

Request	or Records Disposition Authority - Continuation	JOB NO.	• •	PAGE OF	11
7.	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)		SAMPLE OR JOB NO	10, ACTION TA	KEN
2  <u>(</u> D-31)	Destroy (by erasure) individual data elements 10 yeafter entry.  New Drug Evaluation Management Information System ( This system maintains information relative to the receipt and review of investigational new drugs (IN new drug applications (NDA's), and related types of submissions.  Destroy (by erasure) individual data elements 10 years	(ADP)	NC1-88-79	-2/D-31	
2 <b>2</b> (D-32)	Radioactive Drug Research Information System (ADP) This system maintains information relative to the receipt and review of submissions from radioactive research committees.  Destroy (by erasure) individual data elements 10 yeafter entry.	-	NC1-88-79	-2/D-32	
23(D-33)	Drug Product Defects (ADP)  This system maintains a comprehensive file of probl data collected on drug products to determine whethe the problem is peculiar to the product itself, migh occur in other products made by that company, or if problem is an industry-wide phenomenon.  Destroy (by erasure) individual data elements 10 ye after entry.	r t the	NC1-88-79	-2/D-33	
24 (D-34)	Bioresearch Monitoring Information System (ADP)  This system maintains data files on clinical investigators and will maintain data on clinical and nonclinical facilities associated with an investigational new drug (IND). Data will be update periodically and reports prepared which will facilit the monitoring of human drug trial efforts.  Destroy (by erasure) individual data elements as the are updated or 10 years after entry, whichever is sooner.	ed cate	NC1-88-79	-2/D-34	

Request for	Records Disposition Authority—Continuation	JOB NO		PAGE OF
7. ITEM NO	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)		9. SAMPLE OR JOB NO	10. ACTION TAKEN
25 (D-35)	OTC Information System (ADP)			
	This system will maintain data on regulatory act correspondence with drug manufacturers and revie panels, comments on proposed monographs, and bibliographic citations relative to the establis of OTC drug monographs.	W	NC1-88-79	-2/D-35
	Destroy (by erasure) individual data elements 10 after entry.	years		
26 (D-36)	Drug Experience Information System (ADP)			
	This system maintains data files consisting of acreactions to marketed drugs as reported by manufacturers, hospitals, and physicans. Tables generated showing adverse reaction and/or drug interactions, as well as other reports in respons specific requests.	are	NC1-88-7	9-2/D-36
	Destroy (by erasure) individual data elements 30 after entry.	years		
D-37	Drug Efficacy Study Implementation Data System (A This system maintains data related to drug product studied by the National Academy of Science/National Research Council as a result of the 1962 amendment the Food, Drug, and Cosmetic Act. Reports are generated to assist the Agency with administration the Drug Efficacy Study Implementaction (DESI) production (besides) by the Destroy (by erasure) entire file 5 years after termination of DESI program, and any resulting litigation	ts al ts to	NC1-88-79	- 2/D-37
27 (D-38)	Drug Abuse Treatment Monitoring Information System This system maintains data files on the use of methadone and other treatment modalities in drug a treatment programs. The file includes historical the results of periodic Agency inspections, staffiand annual report information.	buse	NC1-88-79	-2/D-38

Request fo	or Records Dispositio Authority—Continuation	NO .	PAGE OF
7. ITEM NO	8. DESCRIPTION OF ITEM (With Inclusive Dates or Retention Periods)	9. SAMPLE OR JOB NO	10. ACTION TAKEN
	Destroy (by erasure) individual data elements 10 years after entry.		Sterk
<b>2</b> 8 (D-39)	Biopharmaceutical Review Management Information System (ADP)	,	
	This system maintains a data base of information pertaining to all new drug applications (NDA's), investigational new drugs (IND's), abbreviated new dru applications (ANDA's) and Antibiotic forms 5 and 6 tha have completed biopharmaceutical review.	NC1-88-79 g t	-2/D-39
	Destroy (by erasure) individual data elements 10 years after entry.		
29(D-40)	Poison Control System (ADP)		·
	This system provides immediate response to selected poison control centers using cathode ray tubes on questions concerning the accidental ingestion of household products and medicines.	NC1-88-79	-2/D-40
	Destroy (by erasure) individual data elements 30 years after entry.		
D-41	Deleted.		
-			